UK markets closed

Active Biotech AB (publ) (0GQU.L)

LSE - LSE Delayed price. Currency in SEK
Add to watchlist
2.8500+1.3420 (+88.99%)
At close: 02:06PM BST
Full screen
Previous close1.5080
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range1.5040 - 1.5040
52-week range1.5040 - 1.5040
Avg. volumeN/A
Market cap348.236M
Beta (5Y monthly)0.86
PE ratio (TTM)N/A
EPS (TTM)-0.2520
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Annual General Meeting of Active Biotech AB

    The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical attendance. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2021, and that the Company’s accumulated loss shall be carried forward. The members of the Board and the CEO were discharged

  • Globe Newswire

    FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis

    Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. “The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for Active Biotech”, said Helén Tuvesson, CEO Active Biotech. “It opens an important regulatory pathway and provides us with the potential to rapidly advance the developm

  • Globe Newswire

    Annual Report 2021 Active Biotech AB (publ)

    Active Biotech's Annual Report 2021 is now available for download at The Annual Report will only be digitally distributed. Download as PDF Lund, April 28, 2022 Active Biotech AB (publ) Helén Tuvesson CEO For further information, please contact: Helén Tuvesson, CEO, tel. +46 46 19 21 56, Hans Kolam, CFO, tel. +46 46 19 20 44, This information is information that Active Biotech AB is obliged to make public pursuan